S. Susnjar (Belgrade, Serbia)
Institute for Oncology and Radiology of SerbiaAuthor Of 1 Presentation
123P - Clinical and pathological characteristics of male breast cancer at the Institute for Oncology including first line treatment in hormone receptor positive tumors
Abstract
Background
Male breast cancer (MBC) is a rare disease that accounts for less than 1% of all diagnosed breast cancers and less than 1% of all cancers in men. Prognosis depends upon tumour size, histological grade, nodal status, hormone receptor status and it is equivalent to that in stage-matched female patients.
Methods
In this study we retrospectively evaluated consecutive data from medical records 166 MBC cases diagnosed from 1991 to 2020 at the Institute for Oncology and Radiology of Serbia.
Results
Median age at diagnosis was 65 years (range 29-90). Most patients were diagnosed in clinical stage II and III (77%). Modified radical mastectomy was performed in about 75%, while others underwent simplex mastectomy or wide excision. Invasive ductal carcinoma was the most common histological type (71,7%), predominantly grade 2 (73,5%). Most tumours were less than 5 cm in diameter (69,3%). About 35,5% of patients had negative axillary lymph nodes involvement, 19,9% up to 3 positives, 19,9% had more than 3 positive axillary lymph nodes. Most tumours were oestrogen and progesterone receptor positive (63,2%), for about 32% hormone receptor status is unknown (data from '90), and only three patient had human epidermal growth factor receptor 2, HER 2 positive breast cancer. About 38% of patients were treated with adjuvant chemotherapy, 64,5% had adjuvant hormonotherapy, 56,6% had postoperative radiotherapy. During period of follow-up (range 1- 11 years) 36,7% of patients had relapse of disease (61/166): locoregional in 10,8% (18/166), bones only 12% (20/166), visceral organs 13,8% (23/166). They were predominantly treated with systemic hormonotherapy (44/61), mostly tamoxifen, 20 patients received chemotherapy, 31 patient underwent palliative radiotherapy. During follow-up 56 patients died due to disease progression (33,7%).
Conclusions
MBC patients had more advanced disease at the presentation. Like postmenopausal women majority of the tumours were hormone receptor positive, treated mainly on the same principles as female breast cancer. Ongoing analysis will compare survival in females with breast cancer matched with known prognostic factors.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.